Cellceutix Selected for Poster Presentation on Kevetrin at 2013 ASCO Meeting

BEVERLY, MA – Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, announces that the Company’s abstract on Kevetrin, Cellceutix’s flagship cancer drug candidate in clinical trials at Dana-Farber Cancer Center, has been accepted for poster presentation at the 2013 American Society of Clinical Oncology (“ASCO”) Annual Meeting.  The annual ASCO meeting is being held in Chicago, Illinois from May 31 through June 4, 2013.

The Company’s abstract titled, “A phase I, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors,” was selected for presentation during the “General Poster Session: Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics” portion of the symposium. The authors of the poster presentation include clinical and laboratory physicians and staff involved in the study from Dana Farber, Beth Israel Deaconess, and Massachusetts General Hospital, along with Cellceutix scientists.

Cellceutix was informed that the Scientific Program Committee and ASCO Leadership received more than 5,300 submissions for poster consideration at this year’s meeting.

“We are proud to have been selected to present our research on Kevetrin to the scientific community at ASCO, especially considering the large number applicants this year,” commented Dr. Krishna Menon, Chief Scientific Officer of Cellceutix.  “We are particularly pleased to have been selected for presenting during the high-profile General Poster Session, which allots us additional time for our abstract and extra time for a question and answer session.  We receive many inquiries about Kevetrin and its progression in clinical trials and this year’s ASCO meeting provides a fantastic platform for us to share the research with our peers.”